International Journal of Clinical Oncology

, Volume 22, Issue 3, pp 554–562 | Cite as

Natural course of asymptomatic abnormal prostate findings incidentally detected by CT after intravesical BCG therapy

  • Masashi Matsushima
  • Eiji Kikuchi
  • Hirotaka Akita
  • Akira Miyajima
  • Mototsugu Oya
  • Masahiro Jinzaki
Original Article

Abstract

Background

Detailed information is not currently available on the incidence, natural course, and management of asymptomatic abnormal prostate findings incidentally detected by radiologic evaluations after BCG therapy for non-muscle-invasive bladder cancer patients.

Methods

We identified 38 patients who were evaluated by contrast-enhanced CT scans before TUR-BT and after BCG therapy between 2006 and 2012. We evaluated the clinical courses of patients with abnormal radiologic findings of the prostate gland after BCG therapy.

Results

Abnormal findings on CT scans were found in the prostate glands of 11 of the 38 patients examined (28.9%), none of whom exhibited any sign or symptom associated with prostatitis. Abnormal findings included a low attenuation area (n = 6, 15.8%), contrast enhancement (n = 3, 7.9%), and a low attenuation area and contrast enhancement in the prostate gland (n = 2, 5.3%). During the follow-up, abnormal prostate findings disappeared spontaneously in most cases without any anti-bacterial or anti-tuberculous drug treatments. No significant differences were observed in patient clinical backgrounds, with the exception of post-BCG prostate volumes, between patients with and without abnormal CT findings. Furthermore, no significant differences were noted in the incidence of the adverse effects of BCG therapy, tumor recurrence rates, or progression rates between patients with and without abnormal CT findings of the prostate gland after BCG therapy.

Conclusions

Asymptomatic abnormal prostate findings incidentally detected by CT after BCG therapy are not rare, and these disappear over time during the follow-up period without any treatment.

Keywords

BCG NMIBC Prostate CT Bladder cancer 

References

  1. 1.
    Lamm DL, Stogdill VD, Stogdill BJ et al (1986) Complications of bacillus Calmette–Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 135(2):272–274PubMedGoogle Scholar
  2. 2.
    Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette–Guerin in the treatment of superficial bladder tumors. J Urol 116(2):180–183PubMedGoogle Scholar
  3. 3.
    Ma W, Kang SK, Hricak H et al (2009) Imaging appearance of granulomatous disease after intravesical bacille Calmette–Guerin (BCG) treatment of bladder carcinoma. Am J Roentgenol 192(6):1494–1500CrossRefGoogle Scholar
  4. 4.
    Suzuki T, Takeuchi M, Naiki T et al (2013) MRI findings of granulomatous prostatitis developing after intravesical bacillus Calmette–Guerin therapy. Clin Radiol 68(6):595–599CrossRefPubMedGoogle Scholar
  5. 5.
    Luftenegger W, Ackermann DK, Futterlieb A et al (1996) Intravesical versus intravesical plus intradermal bacillus Calmette–Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 155(2):483–487CrossRefPubMedGoogle Scholar
  6. 6.
    Suzuki S, Shinohara N, Harabayashi T et al (2002) Complications of bacillus Calmette–Guerin therapy in superficial urothelial cancer: clinical analysis and implications. Int J Clin Oncol 7(5):289–293PubMedGoogle Scholar
  7. 7.
    Jallad S, Goubet S, Symes A et al (2014) Prognostic value of inflammation or granuloma after intravesical BCG in non-muscle-invasive bladder cancer. BJU Int 113(5b):E22–E27CrossRefPubMedGoogle Scholar
  8. 8.
    Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2003) The side effects of bacillus Calmette–Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44(4):423–428CrossRefPubMedGoogle Scholar
  9. 9.
    Bassi P, Milani C, Meneghini A et al (1992) Clinical value of pathologic changes after intravesical BCG therapy of superficial bladder cancer. Urology 40(2):175–179CrossRefPubMedGoogle Scholar
  10. 10.
    Pieras-Ayala E, Palou-Redorta J, Tomero-Ruiz JI et al (2001) Prognostic value of cystocopically pseudotumoral lesions (inflammation/granuloma) in primary stage T1 grade 3 bladder tumors treated with BCG. Int Urol Nephrol 33(3):469–472CrossRefPubMedGoogle Scholar
  11. 11.
    Torrence RJ, Kavoussi LR, Catalona WJ et al (1988) Prognostic factors in patients treated with intravesical bacillus Calmette–Guerin for superficial bladder cancer. J Urol 139(5):941–944PubMedGoogle Scholar
  12. 12.
    Babjuk M, Burger M, Zigeuner R et al (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4):639–653CrossRefPubMedGoogle Scholar
  13. 13.
    Jinzaki M, Kikuchi E, Akita H et al (2016) Role of computed tomography urography in the clinical evaluation of upper tract urothelial carcinoma. Int J Urol 23(4):284–298CrossRefPubMedGoogle Scholar
  14. 14.
    Jinzaki M, Tanimoto A, Shinmoto H et al (2007) Detection of bladder tumors with dynamic contrast-enhanced MDCT. Am J Roentgenol 188(4):913–918CrossRefGoogle Scholar
  15. 15.
    Takeda T, Kikuchi E, Yuge K et al (2009) Discontinuance of bacille Calmette-Guerin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence. Urology 73(6):1318–1322CrossRefPubMedGoogle Scholar
  16. 16.
    Miyashita H, Troncoso P, Babaian RJ (1992) BCG-induced granulomatous prostatitis: a comparative ultrasound and pathologic study. Urology 39(4):364–367CrossRefPubMedGoogle Scholar
  17. 17.
    Rubenstein JB, Swayne LC, Magidson JG et al (1991) Granulomatous prostatitis: a hypoechoic lesion of the prostate. Urol Radiol 13(2):119–122CrossRefPubMedGoogle Scholar
  18. 18.
    Logan JK, Walton-Diaz A, Rais-Bahrami S et al (2014) Changes observed in multiparametric prostate magnetic resonance imaging characteristics correlate with histopathological development of chronic granulomatous prostatitis after intravesical bacillus Calmette–Guerin therapy. J Comput Assist Tomogr 38(2):274–276CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Andius P, Holmang S (2004) Bacillus Calmette–Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 93(7):980–984CrossRefPubMedGoogle Scholar
  20. 20.
    Oates RD, Stilmant MM, Freedlund MC et al (1988) Granulomatous prostatitis following bacillus Calmette–Guerin immunotherapy of bladder cancer. J Urol 140(4):751–754PubMedGoogle Scholar
  21. 21.
    Rischmann P, Desgrandchamps F, Malavaud B et al (2000) BCG intravesical instillations: recommendations for side-effects management. Eur Urol 37(suppl 1):33–36CrossRefPubMedGoogle Scholar
  22. 22.
    Uzoh CC, Uff JS, Okeke AA (2007) Granulomatous prostatitis. BJU Int 99(3):510–512CrossRefPubMedGoogle Scholar
  23. 23.
    LaFontaine PD, Middleman BR, Graham SD Jr et al (1997) Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy. Urology 49(3):363–366CrossRefPubMedGoogle Scholar
  24. 24.
    Mukamel E, Konichezky M, Engelstein D et al (1990) Clinical and pathological findings in prostates following intravesical bacillus Calmette–Guerin instillations. J Urol 144(6):1399–1400PubMedGoogle Scholar
  25. 25.
    Alexander RB, Mann DL, Borkowski AA et al (2004) Granulomatous prostatitis linked to HLA-DRB1*1501. J Urol 171(6 pt 1):2326–2329CrossRefPubMedGoogle Scholar
  26. 26.
    Balasar M, Dogan M, Kandemir A et al (2014) Investigation of granulomatous prostatitis incidence following intravesical BCG therapy. Int J Clin Exp Med 7(6):1554–1557PubMedPubMedCentralGoogle Scholar
  27. 27.
    Stillwell TJ, Engen DE, Farrow GM (1987) The clinical spectrum of granulomatous prostatitis: a report of 200 cases. J Urol 138(2):320–323PubMedGoogle Scholar
  28. 28.
    Kamat AM, Hegarty PK, Gee JR et al (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 63(1):4–15CrossRefPubMedGoogle Scholar
  29. 29.
    Jinzaki M, Matsumoto K, Kikuchi E et al (2011) Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. Am J Roentgenol 196(5):1102–1109CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2017

Authors and Affiliations

  • Masashi Matsushima
    • 1
  • Eiji Kikuchi
    • 1
  • Hirotaka Akita
    • 2
  • Akira Miyajima
    • 1
  • Mototsugu Oya
    • 1
  • Masahiro Jinzaki
    • 2
  1. 1.Department of UrologyKeio University School of MedicineTokyoJapan
  2. 2.Department of Diagnostic RadiologyKeio University School of MedicineTokyoJapan

Personalised recommendations